ViroGates Equity Story
ViroGates is an in-vitro diagnostic company focused on improving patient outcomes through developing and commercializing novel diagnostic tests. With a strong track record of innovation, the company has developed a unique technology platform that enables rapid and reliable measurement of its biomarker-product suPARnostic® in blood samples.
ViroGates is well-positioned to capture a significant share of the rapidly growing market for diagnostic tests, driven by the increasing demand for personalized and precision medicine. The company's flagship product, suPARnostic®, is a groundbreaking test that measures the level of suPAR, a protein biomarker associated with inflammation and disease severity, in patient blood samples. This test has demonstrated significant clinical utility in various diseases, including COVID-19, sepsis, cardiovascular disease etc.
ViroGates has a robust intellectual property portfolio, including multiple patents on its use cases. The company has also established strategic partnerships with leading healthcare organizations, including hospitals, academic institutions, and research centers, to further develop and validate its diagnostic tests.
With a highly experienced management team and a dedicated workforce, ViroGates is well-equipped to execute its growth strategy and capitalize on the significant market opportunity. The company is committed to expanding its product portfolio and commercializing its diagnostic tests globally, with a focus on high-growth markets in Europe and, subsequently, North America and Asia.
Investing in ViroGates offers the opportunity to participate in the growth of a cutting-edge in-vitro diagnostic company with a strong value proposition and significant market potential.
ViroGates' shares (VIRO) have been listed on Nasdaq First North Growth Market Denmark since 2018.
* Other includes analysis services, freight and handling